Company:  OREXIGEN THERAPEUTICS, IN ... (OREX)
Form Type:  10-Q
Filing Date:  5/10/2012 
CIK:  0001382911 
Address:  3344 N. TORREY PINES CT.
SUITE 200
 
City, State, Zip:  LA JOLLA, California 92037 
Telephone:  (858) 875-8600 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$7.54  
Change: 
0.29 (4.00%)  
Trade Time: 
Mar 27  
Market Cap: 
$932.91M
Trade OREX now with

Description of Business
Orexigen® Therapeutics, Inc. ("Orexigen," "we," "our" and "us") is a biopharmaceutical company focused on the treatment of obesity. Our product, Contrave®, was approved in the United States by the U.S. Food and Drug Administration, or FDA, in September 2014 as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index, or BMI, of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). In October 2013, we submitted an application for marketing authorization with the European Medicines Agency, or EMA, for Contrave under the name Mysimba(TM).
Register and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      ITEM 1. FINANCIAL STATEMENTS
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        NOTES TO UNAUDITED FINANCIAL STATEMENTS
      ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
      ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 4. CONTROLS AND PROCEDURES
    PART II. OTHER INFORMATION
      ITEM 1. LEGAL PROCEEDINGS
      Item 1A. Risk Factors.
      ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF ...
      ITEM 3. DEFAULTS UPON SENIOR SECURITIES
      ITEM 4. MINE SAFETY DISCLOSURES
      ITEM 5. OTHER INFORMATION
      ITEM 6. EXHIBITS
    SIGNATURES
    INDEX TO EXHIBITS
  EXHIBIT 10.2
  EXHIBIT 31.1
    CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
  EXHIBIT 31.2
    CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,